Fostemsavir is a novel antiretroviral drug specifically designed for the treatment of adult patients with multiply drug-resistant HIV-1 infection. As an HIV-1 gp120-directed attachment inhibitor, it inhibits viral replication by blocking the binding of the virus to host cells.

How Effective is Fostemsavir in Treatment?

Rapid Reduction of Viral Load

During the functional monotherapy phase, Fostemsavir can significantly reduce the level of HIV-1 RNA in patients' plasma.

A marked decrease in viral load can be observed in most patients within a short period, laying the foundation for subsequent combination therapy.

Synergistic Effect in Combination Therapy

Fostemsavir must be used in combination with other antiretroviral drugs.

Clinical trials have shown that when used in combination with optimized background therapy (OBT), it can help patients achieve virologic suppression, and some patients even attain long-term stable therapeutic effects.

Support for Immune Reconstitution

By effectively inhibiting viral replication, Fostemsavir contributes to the gradual recovery of CD4+ T-cell count and improves patients' immune function.

Population for Which Fostemsavir Is Indicated

Patients with Multiply Drug Resistance

It is indicated for adult patients who have previously received multiple antiretroviral treatment regimens and whose current treatment has failed due to drug resistance, intolerance, or safety issues.

Patients with Extensive Treatment Experience

Patients should have a rich history of antiviral treatment and have limited fully active drugs remaining (usually no more than two classes).

Medication Monitoring for Fostemsavir

Virologic and Immunologic Monitoring

Regularly test the level of HIV-1 RNA to assess virologic response.

Monitor CD4+ T-cell count to track the recovery of immune function.

Cardiac Monitoring

Fostemsavir may prolong the QT interval. Regular electrocardiographic (ECG) examinations are required, especially when it is used in combination with other QT-prolonging drugs or when patients have a history of heart disease.

Liver Function Monitoring

Patients with concurrent hepatitis B or C infection need enhanced liver function testing to be alert to hepatitis recurrence or drug-induced liver injury.

Monitoring of Drug Interactions

Concomitant use with strong CYP3A inducers (such as rifampicin, St. John's Wort) should be avoided to prevent a reduction in Fostemsavir's efficacy.

Dose adjustments are necessary when used in combination with certain statins or oral contraceptives.